Transfusion indications for patients with cancer

Area of Science:

• Hematology
• Transfusion Medicine
• Oncology

Background:

• Anemia and coagulopathies are significant concerns in patient management.
• Focus on red blood cell (RBC) and plasma coagulation factor replacement therapies.

Purpose of the Study:

• To review current concepts and clinical applications of RBC and coagulation factor replacement.
• To inform management strategies for anemia and coagulopathies, particularly in cancer patients.

Main Methods:

• Literature review of clinical studies.
• Focus on RBC transfusion indications and outcomes.
• Evaluation of coagulation factor replacement for cancer-associated coagulopathies.

Main Results:

• RBC transfusions typically indicated at hemoglobin levels of 7 g/dL, with higher levels considered for cancer patients experiencing fatigue.
• Leukoreduced RBCs are standard for cancer patients; transfusions for mild abnormalities are not indicated.
• Data on coagulation factor replacement for invasive procedures with INR < 2 are inconclusive.

Conclusions:

• RBC transfusion indications are increasingly conservative, with safe and effective lower hemoglobin maintenance.
• Coagulation factor replacement is generally not required for most mild coagulopathies.